Genzyme to Build Additional Plant to Support Growth of Myozyme® and Lumizyme®
CAMBRIDGE, Mass.—Genzyme Corp. today announced that it will build an additional manufacturing plant in Geel, Belgium, to support the long-term growth of Myozyme® and Lumizyme® for Pompe diseaseA rare genetic disease in which the body cannot properly break down...BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
Jan. 19, 2011—BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has initiated a Phase 1/2 trial for BMN 701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA) in development for the treatment of Pompe...2010 AMDA Research Grant Awarded to Dr. Andrea Amalfitano
In 2010 the AMDA solicited grant applications from researchers around the world. After careful consideration and consultation with our Scientific Advisory Board, Dr. Amalfitano of Michigan State University was selected as the recipient of the First Annual AMDA...
BMN-701: Potentially More Effective Treatment Option For Pompe
Webinar Details Title: BMN-701: Potentially more effective treatment option for Pompe Date: Monday, December 13, 2010 Speaker: Barbara Wuebbels, BioMarinJon Lebowitz,...
Diaphragm Delivery Of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase
Webinar Details Title: Diaphragm Delivery of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase (rAAV1-CMV-GAA) Gene Vector in Patients With Pompe Disease Date: Tuesday, October 26, 2010 Speaker:Barry J Byrne, MD, PhD – University of...